Efficacy and safety of bromocriptine in the treatment of macroprolactinomas

Annales d'Endocrinologie

Volumn 63, Issue 6 I, 2002, Pages 524-531

  Essais O ^a   Bouguerra, R ^b   Hamzaoui, J ^a   Marrakchi, Z ^b   Hadjri, S ^b   Chamakhi, S ^b   Zidi, B ^a   Slama, C Ben ^b  

^a MILITARY HOSPITAL OF TUNIS   (Tunisia)

^b Institut National de Nutrition Tunis   (Tunisia)

Author keywords

Agonist dopamine; Bromocriptine; Prolactinoma; Tumor size

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN; QUINAGOLIDE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL DISEASE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; SEX DIFFERENCE; SIDE EFFECT; TUMOR VOLUME;

ADULT; BROMOCRIPTINE; FEMALE; FOLLOW-UP STUDIES; HORMONE ANTAGONISTS; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0346665836     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Bevan JS, Webster J, Burke CW, Scanlon WF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-40.
2. Biller BM, Molitch ME, Vance M L et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
3. Boukhriss R, Boukhriss L. À propos de 211 cas de tumeurs hypophysaires. Rev Maghrébine d'Endocrinologie - Diabète et Reproduction 1996; 11: 14-35.
4. Bria A, Berger A, Pe Pcak F, Burger A. Nécrose hypophysaire post-rachianesthésie: Cas clinique. Annales d'Endocrinologie 2000; 61: 164-167.
5. Brue T, Pellegrini I, Gunz G et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577-584.
6. Cannavo S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a prolactine-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999; 22: 306-309.
7. Cohen AR, Cooper PR, Kupersmith MJ et al. Visual recovery after transsphenoidal removal of pituitary adenomas. Neurosurgery 1985; 17: 446-452.
8. Colao A, Di Sarno A, Landi ML et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists. J Clin Endocrinol Metab 2000; 85: 2247-2252.
9. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-83.
10. Colao A, Loche S, Cappa M et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998; 83: 2777-80.
11. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82: 2102-2107.
12. Dupuy M, Foubert L, Visot A. Imagerie des apoplexies adénomateuses hypophysaires. MT Endocrinologie 1999; 1 (horssérie): 92-7.
13. Freda PU, Andreadis CI, Khandji AG et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000; 85: 8-13.
14. Grochowicki M, Khalfallah Y, Vighetto A, Berquet S, Sassolas G. Ophtalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502. British Journal of Ophtalmology 1993; 77: 785-788.
15. Grossman A, Besser GM. Prolactinomas. Br Medic J 1985; 290: 182-184.
16. Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary 1998; 1: 69-81.
17. Kvisstborg A, Halse J, Bakke S et al. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol 1993; 128: 301-307.
18. Lamberts SW and Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991; 72: 635-641.
19. Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.
20. Molitch ME, Thormer MO and Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
21. Pernicone PJ, Scheithauer BW, Sebo TJ et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997; 79: 804-812.
22. Petrossians P, De Herder W, Kwekkeboom D et al. Clinical case seminar. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000; 85: 398-402.
23. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macropro lactinomas in men. J Clin Endocrinol Metab 2000; 85: 3053-3057.
24. Tabarin A, Catargi B. Traitement des macroprolactinomes par le quinagolide. Annales d'Endocrinologie 1997; 58: 87-94.
25. Wilson CB. Extensive personal experience: Surgical management of pituitary tumors. J Clin Endocrinol Metab 1997; 82: 2381-2385.